Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
about
Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing SpondylitisFactors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis.Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.Certolizumab pegol in axial spondyloarthritis.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Pharmacological therapy of spondyloarthritis.Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Treatment patterns, complications, and direct medical costs associated with ankylosing spondylitis in Chinese urban patients: a retrospective claims dataset analysis.An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis.Drug survival of anti-tumour necrosis factor α therapy in spondyloarthropathies: results from the Spanish emAR II Study.Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature reviewAnti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky.A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and ConsequencesThe current standard of care and the unmet needs for axial spondyloarthritis
P2860
Q28546596-59AABDE7-FDEB-418E-BEB1-68DF4281663EQ30725001-13B8C844-1704-4CA5-BFFC-8508E6503838Q34208252-FEFF9AF9-9336-4AEE-B896-3A51012A8AE1Q35708834-B84C75B1-DD48-405E-8BA1-094EB152AC25Q36052215-10712FB8-BEB2-4E95-89DB-1C988AB1EB5FQ36715135-32558E34-1B20-4AB5-9E4A-A5E9013925D0Q36773202-53D36E4F-CE78-485E-99F4-AE07159E8A6BQ37596119-A811734F-F822-402D-B7A9-1BD3C932E704Q38161555-E0E20AFB-4BB4-46FF-B0F5-A5F40F25814AQ38198090-DEF671C9-62A8-408E-A354-9DC3D2F6AED0Q38230740-DD0D83D6-F2AB-43DF-9993-D2037576012FQ38238931-3410D715-F8E8-4345-9BDF-ACC022B338E7Q38527552-878211E8-D09C-4B33-96C8-259F3146AB60Q38611064-C4E6C9E9-EE64-42D0-BB58-FB043226514DQ38828671-5C650170-4C2D-4B8B-9403-9846654E8233Q38914839-FCD04817-D6AB-4399-B140-2D26876E1AE0Q41231679-3BBFAEA0-55DD-4952-8B05-F88E99A6F072Q42701796-62604B2E-B3BF-4E58-9266-430D10D45814Q44915013-82FB4239-8E30-4A8A-8625-BBE04F40B682Q47705810-775C4A92-A52E-40FB-95F5-2D41763A972DQ47870337-CAD46E22-ADD3-48E5-BEC6-7F27A199127EQ50948928-6165CD70-B7C2-4A0A-A261-C117E53679C9Q51036235-CFCD6747-83A5-48A8-A9EC-A8F8E37669D6Q54243018-C58DCC16-ADE6-40F4-9B4B-AE2C6A103369Q54986979-239F7C80-6CBE-4F58-B1BF-605FD034A224Q58800375-32BDFD57-E6D6-4BA7-9D63-A60DB3FB1382Q59134860-6BF61AED-8411-4179-8F76-EA6DF1828EAB
P2860
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@en
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@nl
type
label
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@en
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@nl
prefLabel
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@en
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@nl
P2093
P2860
P50
P1476
Clinical response, drug surviv ...... sh nationwide DANBIO registry.
@en
P2093
Annette Hansen
Annette Schlemmer
Bente Glintborg
Claus Rasmussen
Dorte Vendelbo Jensen
Leif Ejstrup
Mikkel Østergaard
Natalia Manilo
Niels Steen Krogh
Peter Mosborg Petersen
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-201933
P407
P577
2012-08-31T00:00:00Z